Oragenics Partners with Sterling Pharma for Concussion Treatment Development
Oragenics Partners with Sterling Pharma for Concussion Treatment Development
Key Takeaways (TLDR)
Oragenics secures a manufacturing agreement with Sterling Pharma Solutions for ONP-002, positioning it ahead in the race to develop a treatment for concussions.
Sterling Pharma Solutions will produce Oragenics' ONP-002 under cGMP conditions in North Carolina, supporting the upcoming Phase IIb trials for concussion treatment.
Oragenics' partnership with Sterling Pharma Solutions advances the development of ONP-002, promising a future with better treatments for concussion patients.
Oragenics is pioneering nasal delivery for brain-related conditions, with ONP-002 targeting concussions, showcasing innovation in biotechnology.
Why it Matters
This news is significant as it highlights the advancement of a potential breakthrough treatment for concussions, a condition with limited therapeutic options. The partnership between Oragenics and Sterling Pharma Solutions not only accelerates the development of ONP-002 but also reinforces the importance of domestic manufacturing in the biotech sector. For patients suffering from concussions and related conditions, this represents hope for more effective treatments in the near future.
Summary
Oragenics (NYSE American: OGEN), a pioneering biotechnology firm, has entered into a significant manufacturing agreement with Sterling Pharma Solutions for the production of its innovative drug candidate, ONP-002, aimed at treating concussions. This partnership, highlighted by the production at Sterling's Cary, North Carolina facility under cGMP conditions, is a pivotal step for Oragenics as it gears up for Phase IIb trials slated for next year. The collaboration underscores Oragenics' dedication to advancing U.S.-based pharmaceutical innovation, with CEO Janet Huffman lauding it as a critical milestone in the company's journey. For more details, the full press release can be accessed here.
Oragenics is at the forefront of developing nasal delivery solutions for neurological conditions and infectious diseases, with a portfolio that includes treatments for mild traumatic brain injury and Niemann Pick Disease Type C. The company's commitment to innovation is further demonstrated by its proprietary powder formulation and intranasal delivery device. Investors and interested parties can find the latest updates on OGEN in the company's newsroom at https://ibn.fm/OGEN.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oragenics Partners with Sterling Pharma for Concussion Treatment Development.